Show
Sort by
-
- Journal Article
- A1
- open access
Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID‐ERD : results from two randomized placebo‐controlled phase 3 trials
-
- Journal Article
- A1
- open access
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
-
- Journal Article
- A1
- open access
Respiratory infections and anti-infective medication use from phase 3 dupilumab respiratory studies
-
- Journal Article
- A1
- open access
Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases
-
Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
-
Effect of dupilumab on improving physical activity in patients with severe asthma
-
Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
-
Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis
-
Dupilumab reduces severe outpatient asthma exacerbations, cumulative dose, and total number of days of systemic corticosteroid use among patients with moderate-to-severe type-2 asthma
-
Effect of Dupilumab on patient-reported breathing and rescue medication use